Inventiva reports 1H EPS EUR (94c) vs. EUR ($1.31) in 1H last year

The Company’s net loss stood at (EUR 49M) as of June 30 , compared to (EUR 55.3M) as of June 30, 2023. As of June 30 the Company’s cash and cash equivalents stood at EUR 10.1M, compared to cash and cash equivalents at EUR 26.9 M short-term deposits1 of EUR 0.01M, and long-term deposits2 of EUR 9M as of December 31, 2023. “We are actively engaged in discussions seeking additional financing with the goal of funding the Company through the anticipated Phase III topline results. We believe the recent EUR 20.1 million royalty deal, subscribed bySamsara BioCapital and longstanding shareholders such as BVF Partners, NEA, Sofinnova, and Yiheng, is a powerfulendorsement of our strategy. Their continued support underscores their strong confidence in lanifibranor and ourvision for transforming patient care. We remain confident in the ongoing progress of our Phase III NATiV3 clinical trial.” stated Frederic Cren, Chairman, Chief Executive Officer and cofounder of Inventiva. “We would like to thank our key partners and the clinical trial sites on the Phase III clinical trial for their continued efforts and engagement in our study which is reflected in the progress in the recruitment for NATiV3.”